Abstract 7654: Valve-in-Valve-in-Valve Transcatheter Aortic Valve Replacement: A Systematic Review of Patient-Level Analysis
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.7654 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Abhinandan Singla und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background
As TAVR expands into younger, lower-risk patients, an increasing number will outlive two successive bioprosthetic valves, making valve-in-valve-in-valve (ViViV) intervention an emerging clinical reality. The THIRD multicenter registry reported on 51 patients undergoing three aortic interventions, but only 14 underwent transcatheter procedures at both the second and third interventions. Patient-level data on procedural sequencing, valve combinations, and granular outcomes remain scarce, limiting the ability to counsel patients and plan ViViV procedures.
Methods
We performed a PRISMA 2020 systematic review of MEDLINE, Embase, Scopus, and Google Scholar for case reports and series with patient-level data describing a third aortic valve procedure. After deduplication of 353 records, screening of 197 abstracts, and full-text review of 50 reports, 31 articles met inclusion criteria, yielding 32 patient-level observations. All outcomes were classified per VARC-3 definitions.
Results
Thirty-two patients (median age 77 years; 59.4% male) across 10 countries (2012 to 2026) were included. The dominant sequence was SAVR-TAVR-TAVR (87.5%); four patients underwent TAVR-TAVR-TAVR, a pattern expected to grow as index TAVR recipients age. Structural valve deterioration was the indication in 50%, non-structural dysfunction in 37.5%, and endocarditis in 6.3%. Median interval from first to second intervention was 8.0 years; second to third was 4.0 years. All third procedures were transcatheter (balloon-expandable in 18, self-expanding in 13). Median mean aortic gradient fell from 60 to 11 mmHg, a reduction of 43 mmHg. VARC-3 technical success was 100% (32/32); 30-day device success 100% (21/21 evaluable); 30-day mortality 0/19 evaluable. Coronary obstruction occurred in 1/32 (3.1%); tamponade, valve embolization, and open conversion each in 0/32.
Conclusions
ViViV TAVR is technically feasible with high procedural success and substantial gradient reduction across diverse valve combinations and sequences. The accelerating interval between interventions, 8 years to first reintervention and 4 years to the third, underscores the need for prospective ViViV registries and standardized coronary protection protocols. These findings provide actionable patient-level granularity to inform pre-procedural planning at structural heart programs anticipating growing ViViV volume.
Zitieren
APA
Singla, A., Singh, A., Singh, G., Kaur, G., Lodha, C., Luthra, S., Kayali, M., Ali, S., & Zulqarnain, M. A. (2026). Abstract 7654: Valve-in-Valve-in-Valve Transcatheter Aortic Valve Replacement: A Systematic Review of Patient-Level Analysis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.7654
Vancouver
Singla A, Singh A, Singh G, Kaur G, Lodha C, Luthra S, et al. Abstract 7654: Valve-in-Valve-in-Valve Transcatheter Aortic Valve Replacement: A Systematic Review of Patient-Level Analysis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.7654
BibTeX
@article{Singla2026,
author = {Singla, Abhinandan and Singh, Amritpal and Singh, Gurpreet and Kaur, Gurnoor and Lodha, Chirag and Luthra, Shivansh and Kayali, Majd and Ali, Syed and Zulqarnain, Muhammad A},
title = {Abstract 7654: Valve-in-Valve-in-Valve Transcatheter Aortic Valve Replacement: A Systematic Review of Patient-Level Analysis},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.7654}
}
EUVIMED